Back to top

Kymera Completes Enrollment in KT-621 Atopic Dermatitis Trial

Kymera Therapeutics ( ($KYMR) ) just unveiled an update. On June 25, 2026, Kymera Therapeutics reported that it had completed enrollment in its glo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kymera Therapeutics, Inc. (KYMR)